ClinicalTrials.gg
CompletedNCT07408895Updated Feb 13, 2026

Effect of Injectable Platelet Rich Derivatives on Orthodontic Canine Retraction

An interventional study of Platelet-Rich Plasma (PRP) and Platelet-Rich Fibrin (PRF) in Accelerate Tooth Movement, sponsored by Sana'a University. Completed at 1 site in Yemen. Open to participants aged 17 Years to 29 Years. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Sana'a University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled May 2024, registered Jan 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
17 Years to 29 Years
Sex
All
01

Study summary

This study evaluated the effect of injectable platelet-rich derivatives on the rate of orthodontic canine retraction. Patients requiring orthodontic canine retraction following premolar extraction were enrolled and divided into three groups using a split-mouth design. Injectable platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) were applied to compare their effects on the rate of tooth movement. The outcomes were assessed by measuring the amount of canine retraction over time.

02

Conditions studied

  • Accelerate Tooth Movement
03

In context

Lead sponsor

Sana'a University is the lead sponsor of 27 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years to 29 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy individuals aged 17-29 years (mean age 24 ± 6 years)
  • Diagnosis of Class I bimaxillary protrusion or Class II division 1 requiring first premolar extractions
  • Full permanent dentition
  • Good oral hygiene
  • Non-smokers
  • Not taking medications affecting bone metabolism (e.g., bisphosphonates)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • to therapies (e.g., platelet dysfunction)
  • Severe malocclusion unsuitable for fixed appliances
  • Dental anomalies (size/shape)
  • Systemic syndromes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    PRP vs Control (Split-Mouth)

    Split-mouth group in which one side received platelet-rich plasma (PRP) injection and the contralateral side served as a control without injection during orthodontic canine retraction.

    Biological: Platelet-Rich Plasma (PRP)

  • Experimental
    PRF vs Control (Split-Mouth)

    Split-mouth group in which one side received platelet-rich fibrin (PRF) injection and the contralateral side served as a control without injection during orthodontic canine retraction.

    Biological: Platelet-Rich Fibrin (PRF)

Interventions

  • Autologous platelet-rich plasma prepared from the patient's own blood and injected locally at the experimental side to accelerate orthodontic canine retraction.

  • Autologous platelet-rich fibrin prepared from the patient's own blood and injected locally to accelerate orthodontic canine retraction.

06

What researchers measure

Primary outcomes

  1. Rate of Orthodontic Canine Retraction

    The amount of orthodontic canine movement measured in millimeters.

    Time frame: From baseline (initiation of orthodontic canine retraction) until completion of canine retraction, assessed monthly for up to 4 months.

07

Study locations

1 site
  • Faculty of Dentistry, Sana'a University
    Sanaa, Yemen
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because this study was conducted as part of a master's degree thesis and the data are subject to institutional and ethical restrictions.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07408895
Lead sponsor
Sana'a University
Responsible party
Yusra Ali Al Shawri (Principal Investigator, Sana'a University) — Principal investigator
First posted
Feb 13, 2026
Start date
May 30, 2024
Primary completion
Sep 5, 2024
Completion
Sep 5, 2024
Last update
Feb 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Platelet rich plasma · P-prf

Start the discussion